NorthWest Biotherapeutics Inc (NWBO)

[eagle8]

dstock, thanks for your post.
You wrote about keytruda : "What happened to Merck's SC keytruda? I don't remember TLD from the p3 trial has been released yet ".
I assume you are talking about the trial that started in 2020:
https://clinicaltrials.ucbraid.org/trial/NCT04201873 at UCLA.

DCvax (+poly-ICLC, outpatient clinic already added to the DCvax formula) functions as a placebo arm and DCvax (+poli) + Keytruda as the treatment arm.
So we are looking here to see whether Keytruda can add anything to the fantastic results of DCvax+ poly that we saw in the Nature article.
The study is for rGBM.
The first results should be seen in Jan.2024.

GLTU
If this is indeed the case, Merck will be extra happy, but I think so will we.
And especially the patients with rGBM. Then we are closer to a complete cure for rGBM.
If that is not the case, Merck will have a major problem in 2028 when the Keytruda patent expires.
I must say that I am very curious and hope that we will see the results soon (perhaps only after MHRA approval).